Teclistamab in Multiple Myeloma: Mechanism, Structure and Clinical Trial Results
Teclistamab is a BCMA × CD3 bispecific antibody that redirects T cells to kill multiple myeloma cells in relapsed patients. Read more
Your Trusted Student Notes
Teclistamab is a BCMA × CD3 bispecific antibody that redirects T cells to kill multiple myeloma cells in relapsed patients. Read more
Compare BCMA therapies in multiple myeloma including Teclistamab, CAR-T therapy, and antibody-drug conjugates with mechanisms and clinical outcomes. Read more
BCMA signaling drives plasma cell survival in multiple myeloma through BAFF/APRIL activation of NF-κB, PI3K-AKT, and MAPK pathways. Read more
Explore the structural design, mechanism of action, and clinical applications of bispecific antibodies in cancer immunotherapy for targeted tumor killing. Read more
Comprehensive guide on cancer hallmarks, tumor microenvironment, systemic effects, and therapeutic strategies for students. Read more
Blinatumomab is a first-in-class BiTE immunotherapy for B-ALL. Explore its molecular structure, T-cell redirection mechanism, resistance pathways, and clinical trials. Read more
Effective treatments for Acute Lymphoblastic Leukemia (ALL), including chemotherapy, CAR T-cell therapy, and stem cell transplant. Read more
A CAR-T vector plasmid encodes the engineered receptor that enables T cells to target cancer. It includes key elements for antigen recognition, cell signaling, and controlled gene expression. Read more
Explore the Wnt/β-catenin signaling pathway, a crucial cellular mechanism regulating development, tissue homeostasis, and cancer. Understand its components, regulation, and therapeutic potential in disease. Read more
T cells, or T lymphocytes, are a cornerstone of the adaptive immune system, integral to protecting the body against a wide range of threats including... Read more